Challenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for Tremfya – FiercePharma

When Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bolsterits drugs case.

Indata from an extended phase 3 trial,more than half of adults on Tremfya achieved complete skin clearance at two years,J&J said. More than 70% of patients achieved 20% improvement or betterin joint symptoms.Previously, the drug showed benefits through 24 weeksleadingto an FDA approval last yearand through 52 weeks.

Specifically, among patients who had experienced clinically meaningful skin involvement at baseline, 59% of patients who received Tremfya every four weeksand 53% of those who received the drug every eight weeksexperienced complete skin clearance, J&J said.

About 90% of patients randomized toreceiveTremfya in the study continued their treatment through100 weeks, J&J said.Aside from the skin clearance and joint symptom effects, the two-year data confirmed earlierfindingsdemonstrating the meds benefits tophysical function and other quality-of-life factors, J&J said.

The results further bolster our confidence in the ability of Tremfya to significantly improve the diverse manifestations ofPsAover time, Janssen R&D rheumatology disease area leader Alyssa Johnson said in a statement.

RELATED:J&J's Tremfya grabs psoriatic arthritis nod, setting up a battle with Cosentyx, Taltz and more

Investigators are presenting the data at theInnovations in Dermatology virtual spring meeting.

The resultsgive J&Ja stepped-up talking point in a competitivefield. When Tremfya won itsFDA approval in psoriatic arthritis last year, the company set out to launch its drug against meds from AbbVie, Novartis and Eli Lilly. Plus, Lillys Taltz boastshead-to-head dataover the J&J drug.

RELATED:Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

J&Js Tremfya, first approved inlate 2017 to treat plaque psoriasis,generated$1.35 billion last year.

Follow this link:
Challenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for Tremfya - FiercePharma